Ost-müük CNS Pharmaceuticals, Inc. - CNSP CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.0662 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.025457% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.003235% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 0.01 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 2.582 |
Avatud* | 2.6318 |
Aastane muutus* | 777.27% |
Päeva ulatus* | 2.3327 - 2.7415 |
52 nädala ulatus | 0.16-1.38 |
Keskmine maht (10 päeva) | 92.00K |
Keskmine maht (3 kuud) | 3.97M |
Turukapitalisatsioon | 8.41M |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 40.03M |
Tulu | N/A |
EPS | -0.35 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | Mar 1, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Jun 7, 2023 | 2.6219 | 0.0300 | 1.16% | 2.5919 | 2.7615 | 2.2529 |
Jun 6, 2023 | 2.5820 | 0.3192 | 14.11% | 2.2628 | 2.8911 | 2.2628 |
Jun 5, 2023 | 2.3228 | 0.1896 | 8.89% | 2.1332 | 2.3627 | 2.0236 |
Jun 1, 2023 | 1.8044 | -0.0299 | -1.63% | 1.8343 | 1.8442 | 1.7944 |
May 31, 2023 | 1.7944 | 0.0400 | 2.28% | 1.7544 | 1.8243 | 1.6945 |
May 30, 2023 | 1.6947 | -0.1395 | -7.61% | 1.8342 | 1.8343 | 1.6048 |
May 26, 2023 | 1.8343 | -0.0099 | -0.54% | 1.8442 | 1.9440 | 1.8043 |
May 25, 2023 | 1.9539 | 0.0699 | 3.71% | 1.8840 | 2.0138 | 1.7844 |
May 24, 2023 | 1.9539 | 0.1397 | 7.70% | 1.8142 | 2.0237 | 1.7644 |
May 23, 2023 | 1.8343 | 0.1496 | 8.88% | 1.6847 | 1.9041 | 1.6547 |
May 22, 2023 | 1.7446 | 0.0399 | 2.34% | 1.7047 | 1.7745 | 1.6148 |
May 19, 2023 | 1.5651 | 0.2393 | 18.05% | 1.3258 | 1.5851 | 1.2859 |
May 18, 2023 | 1.3158 | -0.0200 | -1.50% | 1.3358 | 1.6249 | 1.2560 |
May 17, 2023 | 1.2361 | 0.0199 | 1.64% | 1.2162 | 1.2660 | 1.2061 |
May 16, 2023 | 1.2261 | -0.0996 | -7.51% | 1.3257 | 1.3457 | 1.2061 |
May 15, 2023 | 1.3657 | 0.0200 | 1.49% | 1.3457 | 1.4155 | 1.2958 |
May 12, 2023 | 1.3557 | -0.0697 | -4.89% | 1.4254 | 1.4355 | 1.3158 |
May 11, 2023 | 1.4255 | -0.1396 | -8.92% | 1.5651 | 1.5651 | 1.3856 |
May 10, 2023 | 1.5651 | 0.0002 | 0.01% | 1.5649 | 1.6248 | 1.5451 |
May 9, 2023 | 1.6349 | 0.1297 | 8.62% | 1.5052 | 1.6549 | 1.4952 |
CNS Pharmaceuticals, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 14.0273 | 9.45461 | 3.83298 | 7.16863 | 0.21511 |
Müük/Üldine/admin kulud, kokku | 4.68084 | 4.39287 | 1.97864 | 0.86052 | 0.18247 |
Uuringud ja arendus | 9.34645 | 5.06173 | 1.85433 | 0.02127 | 0.03264 |
Ootamatud kulutused (tulu) | 0 | 6.28684 | 0 | ||
Tulud majandustegevusest | -14.0273 | -9.45461 | -3.83298 | -7.16863 | -0.21511 |
Intressitulud (kulu), muud tulud, neto | -0.00929 | -0.00326 | -0.04423 | -0.0467 | -0.00426 |
Muud, neto | 0 | -0.17657 | 0 | ||
Netotulu enne makse | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Netotulu pärast makse | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Netotulu enne erikulusid | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Erakorralised kulud kokku | 0 | ||||
Netotulu | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Arvestatav tulu, v a erikulud | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Arvestatav tulu, koos erikuludega | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Jaotamisele kuuluv netotulu | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Keskmine jaotamisele kuuluv aktsia kohta | 26.3533 | 16.6184 | 13.6479 | 15.712 | 15.712 |
Jaotatav EPS, v a erakorralised kulud | -0.53263 | -0.56912 | -0.28409 | -0.47046 | -0.01396 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Jaotamisele kuuluv normaal-EPS | -0.53263 | -0.56912 | -0.28409 | -0.07033 | -0.01396 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Kogutulu | 0 | 0 | 0 | 0 | 0 |
Kogu tegevuskulu | 2.78177 | 2.79292 | 3.8134 | 3.81132 | 3.60966 |
Müük/Üldine/admin kulud, kokku | 1.26041 | 0.89633 | 1.23539 | 1.14634 | 1.40278 |
Uuringud ja arendus | 1.52136 | 1.89658 | 2.57802 | 2.66498 | 2.20687 |
Tulud majandustegevusest | -2.78177 | -2.79292 | -3.8134 | -3.81132 | -3.60966 |
Intressitulud (kulu), muud tulud, neto | -0.00257 | -0.00224 | -0.00095 | -0.00235 | -0.00375 |
Netotulu enne makse | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Netotulu pärast makse | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Netotulu enne erikulusid | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Netotulu | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Arvestatav tulu, v a erikulud | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Arvestatav tulu, koos erikuludega | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Jaotamisele kuuluv netotulu | -2.78434 | -2.79515 | -3.81435 | -3.81367 | -3.6134 |
Keskmine jaotamisele kuuluv aktsia kohta | 38.8083 | 27.8385 | 27.4438 | 25.4327 | 24.6644 |
Jaotatav EPS, v a erakorralised kulud | -0.07175 | -0.10041 | -0.13899 | -0.14995 | -0.1465 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Jaotamisele kuuluv normaal-EPS | -0.07175 | -0.10041 | -0.13899 | -0.14995 | -0.1465 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Käibevarad kokku | 7.47745 | 15.4958 | 7.89391 | 0.58813 | 0.16219 |
Raha ja lühiajalised investeeringud | 5.00452 | 14.0395 | 7.24129 | 0.28274 | 0.11054 |
Raha ja ekvivalendid | 5.00452 | 14.0395 | 7.24129 | 0.28274 | 0.11054 |
Prepaid Expenses | 2.47293 | 1.45635 | 0.65262 | 0.033 | 0.05165 |
Other Current Assets, Total | 0 | 0.2724 | 0 | ||
Total Assets | 8.75739 | 15.8534 | 7.91208 | 0.68333 | 0.16219 |
Other Long Term Assets, Total | 1.26383 | 0.33414 | 0 | 0.0952 | 0 |
Total Current Liabilities | 2.13557 | 1.90543 | 0.311 | 1.23263 | 0.22073 |
Accounts Payable | 1.52282 | 0.94633 | 0.24367 | 0.12807 | 0.0425 |
Payable/Accrued | 0 | 0.04583 | 0.00079 | 0.015 | |
Accrued Expenses | 0.22495 | 0.5198 | 0.0215 | 0.0236 | 0.0414 |
Notes Payable/Short Term Debt | 0.38779 | 0.43929 | 0 | 0.31692 | 0.12183 |
Other Current Liabilities, Total | 0 | 0.76325 | 0 | ||
Total Liabilities | 2.13557 | 1.90543 | 0.311 | 1.23263 | 0.22073 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 6.62182 | 13.948 | 7.60108 | -0.5493 | -0.05853 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.02793 | 0.02386 | 0.01645 | 0.0127 | 0.01027 |
Additional Paid-In Capital | 41.5768 | 34.8705 | 19.0731 | 7.04927 | 0.15056 |
Retained Earnings (Accumulated Deficit) | -34.9829 | -20.9463 | -11.4885 | -7.61126 | -0.21936 |
Total Liabilities & Shareholders’ Equity | 8.75739 | 15.8534 | 7.91208 | 0.68333 | 0.16219 |
Total Common Shares Outstanding | 27.9272 | 23.8561 | 16.4502 | 15.712 | 15.712 |
Property/Plant/Equipment, Total - Net | 0.01611 | 0.02343 | 0.01817 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 14.7332 | 7.47745 | 11.1558 | 13.8835 | 12.7864 |
Raha ja lühiajalised investeeringud | 12.4405 | 5.00452 | 8.32622 | 6.88557 | 11.0752 |
Raha ja ekvivalendid | 12.4405 | 5.00452 | 8.32622 | 6.88557 | 11.0752 |
Laekumata arved, neto | 3.70177 | 0.13265 | |||
Accounts Receivable - Trade, Net | 0.13265 | 0.13265 | |||
Prepaid Expenses | 2.29267 | 2.47293 | 2.82961 | 3.29615 | 1.57852 |
Total Assets | 15.8719 | 8.75739 | 11.5075 | 14.2385 | 13.1446 |
Property/Plant/Equipment, Total - Net | 0.01273 | 0.01611 | 0.01753 | 0.0209 | 0.02411 |
Other Long Term Assets, Total | 1.12596 | 1.26383 | 0.33414 | 0.33414 | 0.33414 |
Total Current Liabilities | 1.0693 | 2.13557 | 2.40743 | 1.83075 | 1.90176 |
Accounts Payable | 0.48972 | 1.52282 | 1.46157 | 0.89249 | 1.05768 |
Accrued Expenses | 0.30701 | 0.22495 | 0.90122 | 0.76068 | 0.53494 |
Notes Payable/Short Term Debt | 0.27257 | 0.38779 | 0.04463 | 0.17758 | 0.30913 |
Total Liabilities | 1.0693 | 2.13557 | 2.40743 | 1.83075 | 1.90176 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Equity | 14.8026 | 6.62182 | 9.10007 | 12.4078 | 11.2429 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.04003 | 0.02793 | 0.02746 | 0.02738 | 0.02535 |
Additional Paid-In Capital | 52.5298 | 41.5768 | 41.2604 | 40.7538 | 35.7772 |
Retained Earnings (Accumulated Deficit) | -37.7673 | -34.9829 | -32.1878 | -28.3734 | -24.5597 |
Total Liabilities & Shareholders’ Equity | 15.8719 | 8.75739 | 11.5075 | 14.2385 | 13.1446 |
Total Common Shares Outstanding | 40.0325 | 27.9272 | 27.4607 | 27.3795 | 25.3528 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netotulu/algväärtus | -14.0366 | -9.45787 | -3.87721 | -7.3919 | -0.21936 |
Raha majandustegevusest | -13.5383 | -7.31802 | -3.55347 | -0.71639 | -0.1122 |
Mittelikviidsed varad | 1.72384 | 1.29498 | 0.7474 | 6.59174 | 0.05992 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Makstud intressid | 0.00977 | 0.00171 | 0.00399 | 0 | 0 |
Muutused tööjõus | -1.23864 | 0.83378 | -0.42562 | 0.08378 | 0.04725 |
Rahavood investeeringutelt | 4.50908 | 14.1342 | 10.2598 | 1.16098 | 0.22274 |
Rahavoogudesse investeerimine | 0 | -0.045 | 0 | 0.47048 | 0 |
Aktsiate emiteerimine (tagasiost), neto | 4.98657 | 14.2222 | 10.2948 | 0.3905 | 0.10092 |
Laenu väljastamine (kustutamine), neto | -0.47749 | -0.04308 | -0.035 | 0.3 | 0.12183 |
Rahaline kogumuutus | -9.03498 | 6.79821 | 6.68616 | 0.44459 | 0.11054 |
Raha majandustegevusest | 0.01307 | 0.0111 | 0.00196 | ||
Tulu investeeringutelt | -0.00575 | -0.01795 | -0.02012 | ||
Kapitalikulutused | -0.00575 | -0.01795 | -0.02012 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -2.78434 | -14.0366 | -11.2414 | -7.42708 | -3.6134 |
Cash From Operating Activities | -3.0772 | -13.5383 | -10.3015 | -8.30599 | -3.30805 |
Cash From Operating Activities | 0.00338 | 0.01307 | 0.00958 | 0.00621 | 0.003 |
Non-Cash Items | 0.33669 | 1.72384 | 1.40694 | 0.90029 | 0.43068 |
Cash Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Cash Interest Paid | 0.00288 | 0.00977 | 0.00721 | 0.00721 | 0.00421 |
Changes in Working Capital | -0.63292 | -1.23864 | -0.4766 | -1.78541 | -0.12833 |
Cash From Investing Activities | 0 | -0.00575 | -0.00367 | -0.00367 | -0.00367 |
Capital Expenditures | 0 | -0.00575 | -0.00367 | -0.00367 | -0.00367 |
Cash From Financing Activities | 10.5132 | 4.50908 | 4.59191 | 1.15574 | 0.34743 |
Issuance (Retirement) of Stock, Net | 10.6284 | 4.98657 | 4.98657 | 1.41745 | 0.47759 |
Issuance (Retirement) of Debt, Net | -0.11522 | -0.47749 | -0.39466 | -0.26171 | -0.13016 |
Net Change in Cash | 7.43598 | -9.03498 | -5.71327 | -7.15392 | -2.96429 |
Financing Cash Flow Items | 0 | 0 |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group535K+
Kauplejad
87K+
Igakuiste aktiivsete klientide arv
$113M+
Igakuine investeerimise maht
$64M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
CNS Pharmaceuticals, Inc. Company profile
Ettevõttest CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals Inc. on kliiniline farmaatsiaettevõte. Ettevõte keskendub vähivastaste ravimikandidaatide arendamisele aju ja kesknärvisüsteemi kasvajate raviks. Ettevõte arendab oma peamist ravimikandidaati Berubitsiini glioblastoomi raviks. Glioblastoomid on kasvajad, mis tekivad astrotsüütidest, mis on aju tugikoestikku moodustavad tähekujulised rakud. Berubitsiin on antratsükliin, mis kuulub keemiaravimite hulka, mis interkaleerub deoksüribonukleiinhappesse (DNA) ja katkestab topoisomeraas II aktiivsuse, mille tulemuseks on DNA replikatsiooni ja parandamise ning RNA ja valkude sünteesi pärssimine. Ettevõte edendab oma WP1244 ravimitehnoloogia arendamist, mis kasutab antratsükliinil ja distamütsiinil põhinevaid tellinguid, et luua väikemolekulaarseid toimeaineid.
Industry: | Biotechnology & Medical Research (NEC) |
2100 West Loop S Ste 900
HOUSTON
TEXAS 77027-3522
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 535,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com